ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to ...

Parkinson's affects more than 1 million people in the US. Only 10 to 20% of people with Parkinson's experience symptoms ...

“This gene-to-molecule research is crucial for discovery in Alzheimer’s disease. It offers fresh perspectives on how genetic risk factors, such as APOE, influence metabolism and perhaps disease ...

Two Northwestern friends came up with a very helpful way to help Parkinson's patients and now that idea is on the market.

Carrying excess fat in your arms and belly might put you at higher risk for Alzheimer’s disease and Parkinson’s disease, ...

The randomized ACCESS-TAVI study led by PD Dr. Tobias Rheude and DZHK-Prof. Michael Joner from the German Heart Center Munich ...

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with ...

Immutep (IMMP) announces positive clinical results from Cohort B of the TACTI-003 Phase IIb trial. This study evaluates eftilagimod alpha in ...

The following is a summary of “First-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

Robert J. White, 82, of Estero, Fla., and formerly Middlebury, Vt., passed away on Nov. 20, 2024, after a courageous 20-year battle with Parkinson’s disease. Born on April 4, 1942, in Rutland, Vt., to ...